T cells —
Primary human PBMCs engineered with TCR156-45, a high-affinity receptor targeting prostate cancer cells. Captured after 3 hrs of direct contact.
PC3 tumor cells —
PC3 prostate cancer cells engineered to present PAP antigen (PC3-A2-PAP), paired with T cells inside hydrogel Nanovial cavities.
Correlations —
Computed across thousands of tumor–T cell dyads. Shown pairs were absent in pseudo-mixed controls, indicating genuine cell–cell communication.